Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 6/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928440 | 0.81 | MALT1 (0.46) | CFTRMALT1NR3C2ADORA2AADORA2B | |
| SCHEMBL25258265 | 0.76 | CFTR (0.42) | CFTRNTRK1SMN1; SMN2 | |
| SCHEMBL23928409 | 0.71 | MALT1 (0.50) | MALT1 | |
| SCHEMBL30595625 | 0.71 | MALT1 (0.50) | MALT1 | |
| SCHEMBL25302088 | 0.70 | ALDH1A1 (0.50) | CFTRNTRK1AR | |
| SCHEMBL31038423 | 0.70 | ALDH1A1 (0.50) | CFTRNTRK1AR | |
| SCHEMBL31348095 | 0.69 | SMN1; SMN2 (0.48) | CFTRS1PR1SMN1; SMN2KIF11AR | |
| SCHEMBL20265568 | 0.69 | MALT1 (0.47) | MALT1NTRK1ADORA2AADORA2BADORA3 | |
| SCHEMBL2372212 | 0.68 | CFTR (0.65) | CFTRNTRK1 | |
| SCHEMBL31348089 | 0.68 | MALT1 (0.52) | MALT1NR3C2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
| US-12152027-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-26 | — | — | US | disclosed |
| US-20220048916-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-17 | — | — | US | disclosed |
| US-11230545-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| CN-113038948-A | Heterocyclic compounds | 武田药品工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | CFTR 2389/4885MALT1 1/4885NTRK1 4511/4885 |
| US-11230545-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | CFTR 2389/4885MALT1 1/4885NTRK1 4511/4885 |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | CFTR 2389/4885MALT1 1/4885NTRK1 4511/4885 |
| US-12152027-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | CFTR 2389/4885MALT1 1/4885NTRK1 4511/4885 |
| US-20220048916-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | CFTR 2389/4885MALT1 1/4885NTRK1 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.